Rahway: Merck & Co is seeking GLP-1 treatments with benefits beyond weight loss, CEO Robert Davis said on Thursday at a conference.
Newer diabetes and weight-loss drugs of the GLP-1 class like Novo Nordisk's Wegovy and Ozempic and Eli Lilly's Mounjaro and Zepbound are expected to together generate annual sales of over $100 billion by the end of the decade.
Merck's experimental drug efinopegdutide, which belongs to the GLP-1 class and is being developed as a treatment for non-alcoholic steatohepatitis (NASH), also showed a "compelling" weight-loss benefit.
Showing benefits beyond weight loss will potentially make it easier to get reimbursement for the drugs, Davis said.
"I think everyone recognizes weight management is a hard thing to get reimbursed. But if you can show cardiovascular outcome, if you can show diabetes outcome, which you're starting to see data for, if you can see fatty liver disease benefits...that is an area where we think there's opportunity," he said.
GLP-1 drugs, which work by helping control blood sugar levels and triggering a feeling of fullness, are also being studied to see whether they can improve health in other ways.
Data from last year suggested that semaglutide, the active ingredient of Wegovy and Ozempic, may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diabetes patients.
Bloomberg was the first to report on Davis' comments on Thursday.
Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/merck-seeks-glp-1-drugs-with-benefits-beyond-weight-loss-ceo-2024-01-04/
Read also: Merck gets European Commission nod for two new indications for Keytruda in gastrointestinal cancers
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!